Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study

BACKGROUND: After myocardial infarction, guidelines recommend higher‐potency P2Y12 receptor inhibitors, namely ticagrelor and prasugrel, over clopidogrel. HYPOTHESIS: We aimed to determine the contemporary use of higher‐potency antiplatelet therapy in Canadian patients with non‐ST‐elevation myocardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ashish, Goodman, Shaun G., Tan, Mary, Suskin, Neville, McKelvie, Robert, Mathew, Andrew L., Lutchmedial, Sohrab, Dehghani, Payam, Lavoie, Andrea J., Huynh, Thao, Lavi, Shahar, Philipp, Roger, Khan, Razi, Yan, Andrew T., Radhakrishnan, Sam, Sedlak, Tara, Brunner, Nathan, Kim, Hahn Hoe, Cieza, Tomas, Kassam, Saleem, Fordyce, Christopher B., Heffernan, Michael, Jedrzkiewicz, Sean, Madan, Mina, Ahmed, Shaheeda, Barry, Colin, Dery, Jean‐Pierre, Bagai, Akshay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207978/
https://www.ncbi.nlm.nih.gov/pubmed/33982795
http://dx.doi.org/10.1002/clc.23618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207978/
https://www.ncbi.nlm.nih.gov/pubmed/33982795
http://dx.doi.org/10.1002/clc.23618

Ejemplares similares